Home » Stocks » IMCR

Immunocore Holdings Limited (IMCR)

Stock Price: $41.25 USD -8.06 (-16.35%)
Updated Mar 4, 2021 4:00 PM EST - Market closed
After-hours: $41.20 -0.05 (-0.12%) Mar 4, 5:55 PM
Market Cap 2.09B
Revenue (ttm) 36.61M
Net Income (ttm) -104.89M
Shares Out 41.72M
EPS (ttm) -2.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 4
Last Price $41.25
Previous Close $49.31
Change ($) -8.06
Change (%) -16.35%
Day's Open 49.15
Day's Range 40.00 - 49.15
Day's Volume 112,035
52-Week Range 39.02 - 61.99

News

Benzinga - 1 week ago

The FDA has designated Breakthrough Therapy status to Immunocore Holdings PLC's (NASDAQ: IMCR) tebentafusp (IMCgp100) for the treatment of HLA-A*02:01-positive in adult patients with unresecta...

About IMCR

Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cance... [Read more...]

Industry
Biotechnology
IPO Date
Feb 5, 2021
CEO
Bahija Jallal, Ph.D.
Employees
291
Stock Exchange
NASDAQ
Ticker Symbol
IMCR
Full Company Profile

Financial Performance

In 2019, Immunocore's revenue was 25.67 million, an increase of 8.52% compared to the previous year's 23.65 million. Losses were -103.93 million, 45.1% more than in 2018.

Financial numbers in millions GBP.
Financial Statements